The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Italian report of expanded access for nab-sirolimus in patients with malignant perivascular epithelioid cell tumor (PEComa).
 
Roberta Sanfilippo
Honoraria - Advenchen Laboratories (Inst); Amgen (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Pharmaceutical (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
Consulting or Advisory Role - Boehringer Ingelheim; PharmaMar; Rain Therapeutics
 
Chiara Fabbroni
Honoraria - Advenchen Laboratories (Inst); Amgen (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo Pharmaceutical (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar; Rain Therapeutics
 
Elena Fumagalli
Honoraria - Advenchen Laboratories (Inst); Amgen (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Daiichi Sankyo Pharmaceutical (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
 
Andrea Franza
No Relationships to Disclose
 
Salvatore Provenzano
Honoraria - Advenchen Laboratories (Inst); Amgen (Inst); Arog (Inst); Bayer (Inst); Blueprint Genetics (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo Pharmaceutical (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly O. (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)
 
Paola Collini
No Relationships to Disclose
 
Francesca Gabriella Greco
No Relationships to Disclose
 
Matteo Duca
No Relationships to Disclose
 
Paolo Giovanni Casali
Research Funding - Advenchen Laboratories (Inst); Amgen/Dompé (Inst); Arog (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Daiihi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst)